neurodegeneration

Scientists leverage the natural ability of antibodies to cross the blood-brain barrier and target proteins implicated in neurodegenerative disease.

Researchers built a framework to purposefully identify drug candidates for repurposing.

By fusing a brain-targeted antibody with an antibody that protects neurons from degeneration, scientists developed a new class of drugs that can traverse the blood brain barrier, enabling potential new treatments for Parkinson’s disease, Alzheimer’s disease, and depression.

New discoveries suggest it is on par with therapeutics and speeds the process of recovery and adoption of personalized treatment

Making the rounds of brain-related therapeutic and diagnostic R&D, with a focus on neurodegenerative disease and dementia

University of Arizona researcher looks beyond traditional causes to find novel therapies

Yumanity's YTX-7739 prevents motor function deficits, leads to improved survival of dopaminergic neurons in Parkinson’s disease mouse model

Lilly’s donanemab Phase 2 trial brings positive results

Four compounds show promise against Alzheimer’s

Natural compound attacks Alzheimer’s disease early